TuHURA Biosciences, Inc./NV Logo

TuHURA Biosciences, Inc./NV

Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.

HURA | US

Overview

Corporate Details

ISIN(s):
US49720K1016
LEI:
Country:
United States of America
Address:
10500 UNIVERSITY CENTER DR., 33612 TAMPA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company focused on developing novel technologies and therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company's core mission is to address the challenges of treatment resistance in cancer patients. Its pipeline is built upon distinct technology platforms, including the IMMUNE FX (IFX) innate immune agonist, designed to enhance the efficacy of existing and new cancer treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all TuHURA Biosciences, Inc./NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TuHURA Biosciences, Inc./NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TuHURA Biosciences, Inc./NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea 308430
CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea 049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea 299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea 471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan 7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan 4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea 068270

Talk to a Data Expert

Have a question? We'll get back to you promptly.